Table 1 Cardiovascular parameters.

From: Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease

Group

Sham

CKD

CKD + DAPA

CKD + EPLE

CKD + DAPA + EPLE

LVEDD (mm)

8.9 ± 1.2

8.7 ± 0.3

8.1 ± 0.2

8.8 ± 0.4

8.1 ± 0.2

LVESD (mm)

4.7 ± 0.2

4.5 ± 0.1

4.3 ± 0.2

4.1 ± 0.3

4.3 ± 0.2

Fractional shortening (%)

47.7 ± 1.4

47.7 ± 1.3

47.8 ± 2.2

54.1 ± 1.7#

47.3 ± 2.3

Stroke volume (ml)

0.36 ± 0.01

0.36 ± 0.01

0.35 ± 0.02

0.34 ± 0.02

0.35 ± 0.01

Cardiac output (ml/min)

126 ± 4

128 ± 5

126 ± 8

122 ± 6

125 ± 5

Systolic blood pressure (mmHg)

148.6 ± 4.4

154.5 ± 5.3

141.5 ± 7.1

141.0 ± 6.3

134.2 ± 3.7

Diastolic blood pressure (mmHg)

116.3 ± 4.0

115.3 ± 4.7

108.7 ± 6.1

109.2 ± 4.9

101.7 ± 4.0

LV weight (g)

1.07 ± 0.03

1.13 ± 0.06

1.10 ± 0.10

1.05 ± 0.04

1.03 ± 0.03

  1. Left ventricular (LV) end diastolic diameter (LVEDD), LV end systolic diameter (LVESD), LV fractional shortening, Stroke volume and cardiac output were assessed after 90 days of treatment. Systolic blood pressure, diastolic blood pressure and LV weight. One way ANOVA was used for statistical analysis, mean ± SEM, n = 9–10. #p < 0.05 vs. CKD.
Back to article page